Palatin Technologies Inc New (PTN) ニュース

Palatin Provides Update on Anticipated 2025 Corporate Milestones

Palatin Provides Update on Anticipated 2025 Corporate Milestones PR Newswire CRANBURY, N.J., Jan. 28, 2025...

Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy

Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy PR...

Form 8-K - Current report

Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds

Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds PR Newswire CRANBURY...

Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis

Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results PR Newswire CRANBURY, N.J., Nov...

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November...

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at...

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium

Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th...

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th...